skinny.

Latest / Lymphoma Hub

What are the recent advances in antibody-drug conjugates for lymphoma treatment?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine S. Diefenbach, Perlmutter Cancer Center, New York, US. We asked, What are the recent advances in antibody-drug conjugates for lymphoma treatment?

Diefenbach summarizes key safety and efficacy data on three antibody therapies across the histological subtypes of lymphoma. These comprise: polatuzumab vedotin, an anti-CD79 antibody-drug conjugate; the bispecific antibodies mosunetuzumab, glofitamab, and epcoritamab; and finally, tafasitamab, a novel anti-CD19 monoclonal antibody.

Hosted on Acast. See acast.com/privacy for…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.